Norbert Galldiks, Jan-Michael Werner, Isabelle Stetter, Hannah C Puhr, Thomas S Nakuz, Gabriele Stoffels, Nathalie L Albert, Karl-Josef Langen, Philipp Lohmann, Matthias Preusser
{"title":"Evaluation of early metabolic changes following vorasidenib using FET PET in patients with <i>IDH</i>-mutant gliomas.","authors":"Norbert Galldiks, Jan-Michael Werner, Isabelle Stetter, Hannah C Puhr, Thomas S Nakuz, Gabriele Stoffels, Nathalie L Albert, Karl-Josef Langen, Philipp Lohmann, Matthias Preusser","doi":"10.1093/noajnl/vdae210","DOIUrl":null,"url":null,"abstract":"<p><p>The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase (<i>IDH</i>) inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI showed limited response, with only 11% of patients having objective responses. Studies suggest that serial PET imaging with radiolabeled amino acids, such as <i>O</i> -(2-[<sup>18</sup> F]-fluoroethyl)-L-tyrosine (FET) PET, may provide earlier and more informative assessments of treatment response than MRI. In an initial experience with FET PET, 3 out of 5 patients showed metabolic response to vorasidenib. This highlights FET PET's potential to guide decision-making, though further trials are needed to confirm outcome benefits.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae210"},"PeriodicalIF":3.7000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683584/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase (IDH) inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI showed limited response, with only 11% of patients having objective responses. Studies suggest that serial PET imaging with radiolabeled amino acids, such as O -(2-[18 F]-fluoroethyl)-L-tyrosine (FET) PET, may provide earlier and more informative assessments of treatment response than MRI. In an initial experience with FET PET, 3 out of 5 patients showed metabolic response to vorasidenib. This highlights FET PET's potential to guide decision-making, though further trials are needed to confirm outcome benefits.
3期INDIGO试验表明，异柠檬酸脱氢酶（IDH）抑制剂vorasidenib显著延长了CNS WHO 2级胶质瘤患者的无进展生存期和延迟干预。然而，常规MRI显示的反应有限，只有11%的患者有客观反应。研究表明，放射标记氨基酸的连续PET成像，如O -（2-[18 F]-氟乙基）- l -酪氨酸（FET） PET，可能比MRI更早、更有信息地评估治疗反应。在FET PET的初始经验中，5名患者中有3名对vorasidenib表现出代谢反应。这凸显了FET PET指导决策的潜力，尽管需要进一步的试验来证实结果的益处。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
